<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Human angiogenin is a potent inducer of <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>The association between angiogenin and <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">cancer progression</z:e> and poor outcome in <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e> has been documented, but its significance in <z:mpath ids='MPATH_336'>leukaemias</z:mpath> has not been evaluated </plain></SENT>
<SENT sid="2" pm="."><plain>We evaluated plasma angiogenin levels in 101 previously untreated patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (59 patients) and advanced <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (42 patients) </plain></SENT>
<SENT sid="3" pm="."><plain>Angiogenin levels were significantly higher in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients than in healthy individuals (P &lt; 0.00001) </plain></SENT>
<SENT sid="4" pm="."><plain>Angiogenin levels were also significantly higher in advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> than in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (P = 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>Higher levels of angiogenin correlated with prolonged survival periods in both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients (P = 0.02 and 0.01 respectively) </plain></SENT>
<SENT sid="6" pm="."><plain>We found no correlation between angiogenin plasma level and various patient characteristics, including age, performance status, antecedent haematological disorder, <z:chebi fb="34" ids="35143">haemoglobin</z:chebi>, white blood cell and platelet counts, and poor prognosis cytogenetics </plain></SENT>
<SENT sid="7" pm="."><plain>There was no significant correlation between angiogenin level and complete remission rate and duration in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="8" pm="."><plain>In multivariate analysis, angiogenin concentration retained its significance as a prognostic factor in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (P = 0.03), together with age (P = 0.00007) and <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> (P = 0.03) </plain></SENT>
</text></document>